Novel biomarker and therapeutic target in the targeted therapy for the patients with metastatic renal cell cancer

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462504
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Japanese Foundation for Cancer Research
• Principal Investigator: Takeshi Yuasa 公益財団法人がん研究会, その他部局等, 研究員 (00314162)
• Co-Investigator(Renkei-kenkyūsha): Takahiro Isono 滋賀医科大学, 実験実習支援センター, 准教授 (20176259) ; Yuichi Ishikawa (公財)がん研究会, がん研究所病理センター, センター長 (80222975) ; Yonese Junji (公財)がん研究会有明病院, 泌尿器科, 部長 (70469633)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 腎癌 / 分子標的治療 / 次世代シーケンサー / 遺伝子発現 / 糖枯渇

Outline of Final Research Achievements

Resistance to the targeted therapy is emerging as an obstacle to successful cancer treatment. In this study, we investigated whether N-GlcNAc2-modified proteins induce G2/M arrest and cell death under glucose deprivation in renal cell cancer (RCC), which is sensitive to nutritional stress. Four of seven RCC cell lines produced N-GlcNAc2-modified proteins and led G2/M arrest under glucose deprivation, leading to cell death. The remaining three cell lines did not produce N-GlcNAc2-modified proteins and undergo G1/S arrest, leading to survival. In this study, we demonstrated that the RCC cells which accumulate N-GlcNAc2-modified proteins do not survive with abnormally prolonged unfolded protein response (UPR) pathway. By contrast, cells that do not accumulate N-GlcNAc2-modified proteins survive. Further studies to clarify these findings will lead to the development of novel targeted therapy for RCC.

Free Research Field

泌尿器科腫瘍学